Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States

被引:218
作者
Averhoff, Francisco M. [1 ]
Glass, Nancy [1 ]
Holtzman, Deborah [1 ]
机构
[1] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS, Atlanta, GA 30333 USA
关键词
VIRUS EPIDEMIOLOGY; PREVALENCE; TRANSMISSION; INFECTION; DISEASE; PEOPLE;
D O I
10.1093/cid/cis361
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
An estimated 2%-3% of the world's population is living with hepatitis C virus (HCV) infection, and each year, > 350 000 die of HCV-related conditions, including cirrhosis and liver cancer. The epidemiology and burden of HCV infection varies throughout the world, with country-specific prevalence ranging from < 1% to > 10%. In contrast to the United States and other developed countries, HCV transmission in developing countries frequently results from exposure to infected blood in healthcare and community settings. Hepatitis C prevention, care, and treatment programs must recognize country-specific epidemiology, which varies by setting and level of economic development. Awareness of the global epidemiology of HCV infection is important for US healthcare providers treating foreign-born patients from countries where HCV infection is endemic and for counseling patients who travel to these countries. Countries with a high burden of HCV infection also would benefit from establishing comprehensive prevention, care, and treatment programs.
引用
收藏
页码:S10 / S15
页数:6
相关论文
共 40 条
[1]   Global estimates of prevalence of HCV infection among injecting drug users [J].
Aceijas, Carmen ;
Rhodes, Tim .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2007, 18 (05) :352-358
[2]  
Altaf Arshad, 2006, J Coll Physicians Surg Pak, V16, P622
[3]   Epidemiology of hepatitis C virus infection [J].
Alter, Miriam J. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (17) :2436-2441
[4]  
American Association for the Study of Liver Diseases, 2012, HEP C GUID POCK CARD
[5]  
Arab Republic of Egypt Ministry of Health and Population National Committee for the Control of Viral Hepatitis, EG NAT CONTR STRAT V
[6]   The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 [J].
Armstrong, Gregory L. ;
Wasley, Annemarie ;
Simard, Edgar P. ;
McQuillan, Geraldine M. ;
Kuhnert, Wendi L. ;
Alter, Miriam J. .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (10) :705-714
[7]   A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel [J].
Cornberg, Markus ;
Razavi, Homie A. ;
Alberti, Alfredo ;
Bernasconi, Enos ;
Buti, Maria ;
Cooper, Curtis ;
Dalgard, Olav ;
Dillion, John F. ;
Flisiak, Robert ;
Forns, Xavier ;
Frankova, Sona ;
Goldis, Adrian ;
Goulis, Ioannis ;
Halota, Waldemar ;
Hunyady, Bela ;
Lagging, Martin ;
Largen, Angela ;
Makara, Michael ;
Manolakopoulos, Spilios ;
Marcellin, Patrick ;
Marinho, Rui T. ;
Pol, Stanislas ;
Poynard, Thierry ;
Puoti, Massimo ;
Sagalova, Olga ;
Sibbel, Scott ;
Simon, Krzysztof ;
Wallace, Carolyn ;
Young, Kendra ;
Yurdaydin, Cihan ;
Zuckerman, Eli ;
Negro, Francesco ;
Zeuzem, Stefan .
LIVER INTERNATIONAL, 2011, 31 :30-60
[8]  
Fierer Daniel S., 2011, Morbidity and Mortality Weekly Report, V60, P945
[9]   The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt [J].
Frank, C ;
Mohamed, MK ;
Strickland, GT ;
Lavanchy, D ;
Arthur, RR ;
Magder, LS ;
El Khoby, T ;
Abdel-Wahab, Y ;
Ohn, EA ;
Anwar, W ;
Sallam, I .
LANCET, 2000, 355 (9207) :887-891
[10]   Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission [J].
Gibb, DM ;
Goodall, RL ;
Dunn, DT ;
Healy, M ;
Neave, P ;
Cafferkey, M ;
Butler, K .
LANCET, 2000, 356 (9233) :904-907